A Study to Develop a Pulmonary Hypertension Association Registry (PHAR)

Overview

About this study

The primary purpose of this study is to measure and improve quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

New patients to a PHA Care Center with either newly diagnosed or established PAH or CTEPH (within 6 months of first outpatient visit at the PHCC).
Informed consent for data to be abstracted and included in the PHAR provided by the patient or guardian.
Able to understand and speak either English or Spanish.

Exclusion Criteria:

Any exception to the Inclusion Criteria above.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Robert Frantz, M.D.	Open for enrollment	Contact information: Louise Durst R.N. (507) 284-1838 durst.louise@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Robert Frantz, M.D.

Open for enrollment

Contact information:

Louise Durst R.N.

(507) 284-1838

durst.louise@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials